1.
Donaghey J, Thakurela S, Charlton J, et al. Genetic determinants and epigenetic effects of pioneer-factor occupancy. Nat Genet. 2018;50(2):250-258. doi:10.1038/s41588-017-0034-3.
1.
Yu H, Schreiber SL. Structure of guanine-nucleotide-exchange factor human Mss4 and identification of its Rab-interacting surface. Nature. 1995;376(6543):788-91. doi:10.1038/376788a0.
1.
Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273(5272):239-42.
1.
Rajavelu A, Lungu C, Emperle M, et al. Chromatin-dependent allosteric regulation of DNMT3A activity by MeCP2. Nucleic Acids Res. 2018;46(17):9044-9056. doi:10.1093/nar/gky715.
1.
de Boer CG, Vaishnav ED, Sadeh R, Abeyta EL, Friedman N, Regev A. Deciphering eukaryotic gene-regulatory logic with 100 million random promoters. Nat Biotechnol. 2020;38(1):56-65. doi:10.1038/s41587-019-0315-8.
1.
Chen J, Zheng XF, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A. 1995;92(11):4947-51.
1.
Ho SN, Boyer SH, Schreiber SL, Danishefsky SJ, Crabtree GR. Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists. Proc Natl Acad Sci U S A. 1994;91(20):9203-7.
1.
Sandoval GJ, Pulice JL, Pakula H, et al. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Mol Cell. 2018;71(4):554-566.e7. doi:10.1016/j.molcel.2018.06.040.
1.
Agostini M, Schoenmakers E, Beig J, et al. A Pharmacogenetic Approach to the Treatment of Patients With Mutations. Diabetes. 2018;67(6):1086-1092. doi:10.2337/db17-1236.
1.
Simon JA, Schreiber SL. Grb2 SH3 binding to peptides from Sos: evaluation of a general model for SH3-ligand interactions. Chem Biol. 1995;2(1):53-60.